The point is that there is information here that gives

New Post Public Reply Private Reply Replies (1) Message Board
MGK_2
527
The point is that there is information here that gives understanding to how the effectiveness of the drug is quantified and it is discussed for both mTNBC and NASH. In addition, some light is shed on the 3 mTNBC trials that will be discussed in the approaching ASCO meeting/conference.

I'm answering you here b/c I only have a limited # of posts.

This Proactive was in early January I think.

CytoDyn reveals results from part two of Phase 2 NASH clinical trial



Christine Corrado: Hello there, Welcome back to Proactive NY. With me this morning is Nader Poorhassan, CEO at CytoDyn. Nader, good to see you. Happy New Year. How are you?

Nader Poorhassan: Happy New Year. Good to see you. I'm doing great. Thank you.

CC: Nader, lots to get to today. Let's kick it off with the results you announced this week for your 350mg weekly dose of LL for your phase 2 NASH clinical trial. You have some apparent positive results here?

NP: Yeah, so, whenever there is analysis, there is a primary endpoint, the most important primary focus of everybody. Primary endpoint can be analyzed on the ITT, Intention To Treat population, that means everybody who comes into the trial. Or Per Protocol, PP. That means if somebody didn't finish a trial, or just got involved for a few weeks and got kicked out, or whatever the STAP, statistical analysis plan has dictated, then you take some of the patients out based upon that violation of the protocol and so forth. That's called Per Protocol, PP. So 1) ITT and 2) PP.

In Primary Endpoint, which was PDFF, the fatty deposits, we have hit our Primary Endpoint for both populations. Primary Endpoint, for both populations of ITT and Per Protocol.

Now, lets talk about Secondary Endpoint. That's what some people had confusion. The Secondary Endpoint, when you do the ITT, then you do PP. ITT is everybody. PP is the people who didn't finish the trial and all that. The ITT which showed that we had (a "p" value of ) 0.057. So we are getting close to 0.05. and the PP was like 0.02, it was statistically significant. Now, when we do this with a different methodology, we have all of them statistically significant. Because, there are different ways of doing them. But, we don't want to talk about those things because we want the FDA to get a chance to look at it. But our share holders are very eager, they always want to see the data, so we thought to give them a good news, we hit our Primary Endpoint and Secondary Endpoint in the PP Per Protocol, but the Primary Endpoint was also hit on ITT.

Now, what does that mean for the company? Well, we are sending this TopLine Report that we are finalizing, now, immediately to the FDA and other countries and right now, we are sending it to over 1,000 people from pharmaceuticals, biotech, bigger pharmaceuticals, all over the world, because this data, to us, is going to be able to go forward with Phase 3 and BTD. We believe that. And the data has told us by the statistician and the group that did this analysis, that it is "hands down", "very strong data". But again, we don't want to get to this 0.057. Why wasn't that one statistically significant for secondary endpoint in the ITT group? We can look at it other ways. I have data here that shows certain ways that you can analyze to get better. We did it very conservative. We gave it to a 3rd party. The folks were solid. They have generated all the tables. And we feel very strong about the data.

CC: OK, let's move on from NASH, to your Corona Virus Trial. In the past weeks, you've said you would start your Phase 3 to evaluate LL in Corona Virus in Critically Ill Patients. Have you started that yet?

NP: Well, we are working on that. That trial is CD20. It's for the United States. It will take us a little bit of time to set up the CROs which we are talking to and to date the trial. The focus of everybody should be like this: The FDA has allowed us to do meta-analysis. So, what we want to do is have the same thing perhaps in Brazil. So, we asked ANVISA if they would also give us meta-analysis, which means: you take your double blinded placebo controlled trial, which ever they are, and you can combine that data. So if we do that, with a meta-analysis in a critically ill population, Brazil data, we might only need another 15 or 20 patients, that's all. because you already have 62. So during that 10-15 more, or whatever that number turns out to be, we are talking to the Brazilian folks today, there were 2 weeks we haven't talked to them due to vacation, but this update is a huge update, because the number of cases in Brazil has really gone up, the number of dead, thank God has not gone up that way, but, our ventilation requirement and ICUs are getting more patients, so, we see where our data is, but we could be very very close to analysis of interim analysis in 20 patients perhaps, but these are not finalized, so what I'm saying, everybody should take it with a grain of salt. We are going to take a look at it, talk to Brazilian folks, talk to ANVISA and get back to everybody.

CC: OK, moving from Corona Virus to HIV. What is the status on your BLA?

NP: Well, the BLA on HIV, we are on time. We have got ourselves some really great experts that have added to our team. We moved away from Amarex obviously. So we have that under control now. And we feel very strong now that our BLA, 1st quarter is on track. We will also be meeting FDA hopefully soon and letting everybody know where we are at. But we are on track on that. We are working on the monotherapy Phase 3 Protocol, also, simultaneously.

CC: OK, now lets get to oncology. Specifically, mTNBC. It has been 2 months since you submitted your BTD application to the FDA for this. What is the status there?

NP: So the FDA had a new drug that was approved for mTNBC, which is called sacituzumab. So that drug is now standard of care SOC. Comparing ourselves to chemotherapy, the FDA has seen how strong our results are, but comparing with sacituzumab, we have to show superiority. We haven't done that, so FDA can not give us BTD when you compare it to sacituzumab, but FDA has told us, that we are welcome to give more data. Keep in mind, the data, the 28 patient's that we gave to FDA, if their overall survivability was 12.5 months, with sacituzumab, it's 12 months. So we are a little bit better, not substantially better. Which we need to be substantially better for BTD. But, it has been 3-4 months since we did the analysis, 2 months of waiting for the BTD and a month or so before that when we locked the data. So, that means that if the patients are still alive, we have substantially improved data. We don't know that. We are checking on that. And we do know that some of the patients, we believe most of them or quite a bit of them are alive, but I have to verify that 100% and give that to the FDA and then update our shareholders. There you update the data and submit it, that could be considered as a 2nd application, so it might be another 60 days of waiting. But we feel very very strong about our cancer program and all the patients that are still coming and seeing the results. Share holders should focus. We have patients and physicians talking about how strong this data is and if they have to wait a little bit, here or there, they should not make a big issue about that in my opinion.

CC: Yeah, I appreciate the update on all these indications. As we are now heading into, we are in the new year, 2022, give us a sense of what your cash position looks like. Where are we with funding?

NP: So the cash position is; we put an 8k out, sorry Q out there, I can't give an update on that right now. That showed I think $8million on our balance sheet. Now, we have 200,000,000 shares that were authorized to us by the shareholders. At this time, we are so close to so many amazing milestones, that we can utilize those 200million shares and raise the funds that we need to go forward. But people have to keep in mind also that right now, a partnership for our NASH looks very very solid. We can't wait to have a call with everybody which will be in about 10 days or so hopefully and lay out all the steps on what we are doing on each one of these indications and what are our milestones. NASH, when are we expected to get the BTD? file and get the result. Cancer, the same thing, when we going to update the numbers so we can get that moving and the BLA HIV and Covid 19. With that plan for 2022 and all the milestones laid out, we will do a fund raising based upon that and we believe it will be very successful and a very successful 2022.

CC: Alright, I appreciate the updates here Nader. Thanks so much.

NP: Thank you for having me. I appreciate it.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 0

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 88

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
Asia-Pacific Miracle: New Economic Chapter Unfolds

Updated Category News Views 44

A Fresh Breeze in Asia-Pacific's Sails You ever look around and realize everything's about to change—again? That's Asia-Pacific right now. We're staring down the barrel of a new chapter in what folks are calling the "Asia-Pacific miracle." The text from China Daily paints a picture of a region gearing up to crank the cooperation dial even higher. And where's this...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 74

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 165

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 34

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 159

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 57

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 42

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading

Top 5 Most Recently Viewed Articles

Swinerton Strengthens Leadership in Design-Build Initiatives

Updated Category News Views 250

Swinerton Welcomes Jason Bone as New Design-Build Leader In an exciting development, Swinerton Incorporated has bolstered its design-build leadership by appointing Jason Bone as the Director of National Design-Build. With this strategic move, the company reaffirms its dedication to providing exceptional client experiences while adapting to the evolving demands of the...

Continue Reading
PayPoint plc Announces PDMR Shareholding Updates

Updated Category News Views 144

PayPoint plc PDMR Share Acquisitions The company, PayPoint plc, recently shared exciting news regarding the shareholdings of its key executives, known as Persons Discharging Managerial Responsibilities (PDMRs). These PDMRs are significant players in the company, including its Executive Directors, and they participate in the Share Incentive Plan (SIP) designed to encourage...

Continue Reading
UMH Properties Announces First Quarter 2025 Financial Insights

Updated Category News Views 349

UMH Properties Reports Strong First Quarter Results for 2025 UMH Properties, Inc. (NYSE: UMH) recently revealed its financial results for the first quarter of 2025, showcasing encouraging growth and improvement in various operational metrics. The company reported a total income of $61.2 million for the quarter ending March 31, 2025, reflecting a 6% increase compared to...

Continue Reading
Netcompany Group Launches Share Buyback to Enhance Value

Updated Category News Views 245

Share Buyback Program Update from Netcompany Group Company announcement No. 20/2025 1 September 2025 On 14 August 2025, Netcompany Group A/S announced the initiation of a share buyback program of up to DKK 500 million, aiming to repurchase a total of 3,700,000 shares. This strategic move is designed to adjust the company’s capital structure while also fulfilling...

Continue Reading
Marex Group Investors: Join the Securities Fraud Class Action

Updated Category News Views 190

Recent Class Action Notice for Marex Group plc Investors In a significant announcement, a class action lawsuit has been filed that could impact many investors in Marex Group plc (NASDAQ: MRX). This legal action arises from reports that raise serious allegations regarding the company's financial reporting practices. For those who bought Marex shares, this is a crucial time...

Continue Reading